Trial Profile
Phase I/Ib Study of Nivolumab and Veliparib in Patients With Advanced Solid Tumors and Lymphoma With and Without Alterations in Selected DNA Repair Genes
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Oct 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Veliparib (Primary)
- Indications Diffuse large B cell lymphoma; Extranodal NK-T-cell lymphoma; Lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions
- 27 Oct 2020 Study design changed from Single Group Assignment to Sequential Assignment.
- 28 Apr 2020 Results assessing nivolumab and veliparib in patients with advanced solid tumors and lymphoma with and without alterations in selected DNA repair genes,presented at the 111th Annual Meeting of the American Association for Cancer Research - I
- 07 Aug 2019 Status changed from recruiting to active, no longer recruiting.